Biosimilars Insulin Market: Growth Analysis by 2016 - 2024
Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH.
Request to Sample Report @ https://www.persistencemarketresearch.com/samples/11674
Lilly/Boehringer Ingelheim developed a biosimilar insulin called “Insulin glargine” and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first “biosimilar” insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
Biosimilar insulin proved to have an effective treatment for patients suffering from diabetes mellitus by reducing the cost for the treatment. There are some companies who have developed devices which allow the safe and less painful delivery of biosimilar insulin thus making the device a market differentiator even though it’s chemically equivalent to the branded product. Many companies in the emerging economies have started developing biosimilar insulin due to the favorable regulatory requirements as compared to the companies in developed countries where their stringent regulatory requirements. As the regulatory requirements for the approval process of biosimilars are considerably higher than those required for the generic drugs and entail the comprehensive analysis for each of its characteristics.
Biosimilars have increased the opportunities in healthcare services and have decreased the expenditures creating a significant competition between the companies manufacturing branded products and biosimilars. Globally, the major factors responsible for surging the demand for biosimilars insulin in the market are increase in diagnosed and undiagnosed diabetes, patent expiry for insulin, growing population. Diabetes is considered to be one of the fastest growing disease and attribute to 3 million deaths annually, and has become a pandemic. Increasing poverty level in developing countries has created a pressure on the healthcare industry to develop cost effective products and treatment options especially for diabetes patients. The only aspects which can affect the biosimilars market are safety and efficacy of new biosimilars also the stringent regulatory bodies leading to delayed approvals.
According to the Biosimilars Pipeline Database, there are total 1,357 product entries for biobetters and biosimilars constitute 737 of them (March, 2016). Among the top targeted reference products, insulin and analogs constitute 51 and the companies producing it include Biocon, Mylan N.V., Sanofi, Novo Nordisk and others. Sanofi, a multinational pharmaceutical company is also developing LixiLan, a mix of basal insulin with GLP-1 which is directed to treat for type 2 diabetes. Eli Lilly and Company, a U.S. based company is currently running Phase III clinical trials for a non-insulin drug Empagliflozin (BI10773) targeting the treatment for type 1 diabetes.
Request Report for TOC @ https://www.persistencemarketresearch.com/toc/11674
The new trend in the market is developing ultra-rapid acting insulins to replace Humalog and Novolog (patents expired) which is important for pump users and disorder related to real-time artificial pancreas. There are new attempts made by companies to create oral insulin such as ingestible capsules for better drug delivery. Most of the biosimilars have reached Phase III and are soon to get approved by the respective regulatory bodies and will reach the market with cheaper prices as compared to the branded products. Various multinationals are forming alliances and partnerships to develop biosimilar insulin such as Eli Lilly and Company and Boehringer Ingelheim Gmb, Biocon Limited and Pfizer Inc., Mylan N.V. and Momenta Pharmaceuticals.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilars Insulin Market: Growth Analysis by 2016 - 2024 here
News-ID: 1071452 • Views: 236
More Releases from Persistence Market Research Pvt. Ltd
Global HPMC Capsules Market is expected to reach a Valuation of US$ 554.5 Mn Ove …
HPMC capsules are strictly non-toxic and qualify to be Kosher and Halal-certified, which is why their popularity has grown in several parts of the world. Moreover, these capsules can significantly boost the body metabolism by improving absorption and digestion of protein, fat and carbohydrates. HPMC capsules find their application in the preparation of non-animal based medicines and cosmetics & nutraceuticals products. Persistence Market Research (PMR) recently conducted a study
Vacuum Tissue Processor Technology Most Favored in the Global Tissue Processing …
Persistence Market Research has come up with a fact based analytical research study describing various aspects of the tissue processing systems market across the globe. The analysis on tissue processing systems has been systematically drafted in a new research publication titled “Tissue Processing Systems Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)”. This comprehensive research report focuses on various developments, trends, restraints, opportunities, drivers and challenges impacting revenue growth of
Endodontics Market Is Projected To Grow At A Moderate CAGR During The Period Of …
Endodontics is associated with the dentistry segment. It involves several therapies to protect the human teeth from infections and injuries caused to the dental pulp. Generally, it is concerned with morphology, pathology as well as physiology of dental pulp and the periradicular tissues. Endodontics is important during carrying out root canal procedure in order to reduce the inflammation and to end infection. Modernization has touched the field of endodontics as
Global Home Infusion Therapy Devices Market Driven by Growing Incidence of Pain, …
According to the latest market report published by Persistence Market Research titled ‘Home Infusion Therapy Devices Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025),’ the global Home Infusion Therapy Devices market is expected to expand at a CAGR of 6.8% during the forecast period 2017–2025. Persistence Market Research delivers key insights and presents a revised forecast of the global Home Infusion Therapy Devices market for an eight year period from
More Releases for Biosimilar
Global Biosimilar Drug Sales Market Report 2018
In this report, the global Biosimilar Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Free | Request Sample Copy of the Report @ https://bit.ly/2M8e47Z Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Biosimilar Drug for
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: email@example.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight
“Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014. Trastuzumab or
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.